Evidence map›Paper›PMID 31081948›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2019

Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti-PD-1 monoclonal antibody.

G Richtig, E Ramelyte, L Koch, H Greinix, S Ferrone, R Dummer, E Richtig

Open access · bronzeAbstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

G RichtigOtto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria.ORCID 0000-0002-4437-4413
E RamelyteDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
L KochDepartment of Dermatology, Medical University of Graz, Graz, Austria.
H GreinixDivision of Hematology, Medical University of Graz, Graz, Austria.
S FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
R DummerDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
E RichtigDepartment of Dermatology, Medical University of Graz, Graz, Austria.
Medical University of Graz · ATUniversity Hospital of Zurich · CHHarvard University · US

Funding

T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancerR01DE028172 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XINHUI · 2018 to 2022
$1.9M
ROLE OF THE HLA ANTIGEN PRESENTING MACHINERY (APM) IN RESISTANCE TO PD-1 AXIS BLOCKADE IN NON-SMALL CELL LUNG CANCERR03CA219603 · NCI · YALE UNIVERSITY · PI FERRONE, SOLDANO, SCHALPER, KURT A · 2019 to 2020
$184k
NCI NIH HHS R03 CA219603NIDCR NIH HHS R01 DE028172NIH HHS R01DE028172NIH HHS R03CA219603
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalHumansMaleMelanomaMiddle AgedNeoplasm MetastasisProgrammed Cell Death 1 ReceptorSkin NeoplasmsAntibodies, MonoclonalPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID31081948
PMCPMC8697030
OpenAlexW2945264188

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.